extensive mass of pre-clinical data, a comprehensive description of which can be found in Cancer Research. 1 The current phase III trial also builds on the results of a pilot clinical trial for recurrent GBM patients, the results of which were recently published. 2
Scientific Background
It is generally accepted that low-intensity (1V/cm), medium-frequency (100-300kHz) alternating electric fields have no meaningful biological effects. This assumption is based on the fact that the evidence collected to date suggests they do not cause significant temperature elevation or stimulate excitable tissues such as nerves, muscles in general, the heart muscle or cardiac pacemakers, as they reverse polarity before reaching the threshold of excitation; however, this fact is true only for quiescent cells. Proliferating or dividing cells may be significantly affected by such fields.
There are two major mechanisms by means of which the frequencytuned TTFields specifically affect dividing cells. The first mechanism relates to the non-uniform electric field distribution within dividing cells (see Figure 1B ) compared with the uniform field in quiescent cells (see Figure 1A ). The non-uniformity, which is expressed in field focusing at the narrow cytoplasmatic bridge connecting the two daughter cells, exerts a force on all charged bodies -such as intracellular organellesor dipoles -such as most macromolecules. This force, directed towards the bridge regardless of the field polarity, results in movement of the said charged elements in a process called dielectrophoresis. This movement disrupts the internal cell structure and results in its destruction. The second mechanism relates to the force the field exerts on the microtubule chains and individual dimmers interfering with the polymerisation-depolymerisation process taking place in the spindle during division. This interference interrupts the normal division process.
The end result is that the cancer cell proliferation rate is attenuated and the cells are destroyed without affecting the normal quiescent cells.
Since the TTFields treatment is based on a physical rather than a chemical modality, its affinity and activity is independent of highly specific cell receptors. Therefore, it is hoped that it will affect a wide range of cancer cell types. Indeed, it was preliminarily found to arrest the proliferation of and destroy all 15 types of cancer cell lines tested. 
The Technology

Pilot Study Results
The Proceedings of the National Academy of Sciences recently published the results from an initial pilot study for patients with recurrent glioblastoma treated with TTFields alone. In this single-arm trial, treatment was performed with the NovoTTF device on 10 recurrent GBM patients. Patients were eligible at any recurrence following standard treatments (surgery or biopsy, chemotherapy and radiation) and all patients had previously received temozolomide.
Efficacy analysis was performed by comparing the following end-
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Low-intensity, Medium-frequency Alternating Electric Fields Figure 2) . This is more than double the corresponding reported rates in historical control groups reported in the composite of clinical literature; namely, approximately 9.5 weeks, 15.3% and 29.3 weeks, respectively.
The patients received treatment for a total of 280 weeks without a single treatment-related adverse event. The only device-related side effect was a mild to moderate contact dermatitis beneath the delivering electrode gel. This dermatitis responded well to application of topical cream and periodic electrode relocation.
Ongoing Clinical Studies
Physicians are currently enrolling patients for a phase III pivotal study for 
Alternating current field distribution in and around quiescent (A) and dividing (B) cells. Inside quiescent cells the field is uniform and the oscillating electric forces result only in 'vibration' of ions and dipoles (the forces associated with each half cycle are denoted by the arrows). In contrast, the non-uniform field within dividing cells (B) induces forces pushing all dipoles towards the furrow.
Source: Kirson et al., 2004. 2 Brown trace = NovoTTF-treated patients ± standard error of mean (n=10 
